PE20080316A1 - AZIRIDINYL-EPOTILONE COMPOUNDS - Google Patents
AZIRIDINYL-EPOTILONE COMPOUNDSInfo
- Publication number
- PE20080316A1 PE20080316A1 PE2007000648A PE2007000648A PE20080316A1 PE 20080316 A1 PE20080316 A1 PE 20080316A1 PE 2007000648 A PE2007000648 A PE 2007000648A PE 2007000648 A PE2007000648 A PE 2007000648A PE 20080316 A1 PE20080316 A1 PE 20080316A1
- Authority
- PE
- Peru
- Prior art keywords
- rent
- epotilone
- aziridinyl
- compounds
- substitute
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101100495911 Arabidopsis thaliana CHR10 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
REFERIDA A UN COMPUESTO AZIRIDINIL-EPOTILONA DE FORMULA (X), DONDE K ES O, S O NR7; A ES -(CR8R9)-(CH2)m-Z-; Z ES (CHR10), C(=O), -OC(=O), ENTRE OTROS; B1 ES OH O CIANO Y R1 ES HIDROGENO O B1 Y R1 JUNTOS FORMAN UN ENLACE DOBLE; R2, R3 Y R5 SON H, ALQUILO, ARILO, ENTRE OTROS; R4 ES H, ALQUILO, ALQUENILO, ENTRE OTROS; R6 ES H, ALQUILO O ALQUILO SUSTITUIDO; R12 ES H, ALQUILO, ALQUILO SUSTITUIDO O HALOGENO; R13 ES ARILO, HETEROARILO, ENTRE OTROS; m ES UN ENTERO DE 0 A 6. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CANCERES, EN ESPECIAL AQUELLOS RELACIONADOS CON LA EXPRESION DEL RECEPTOR DE FOLATOREFERRING TO AN AZIRIDINYL-EPOTILONE COMPOUND OF FORMULA (X), WHERE K IS O, S OR NR7; A ES - (CR8R9) - (CH2) m-Z-; Z IS (CHR10), C (= O), -OC (= O), AMONG OTHERS; B1 IS OH OR CYANE AND R1 IS HYDROGEN OR B1 AND R1 TOGETHER FORM A DOUBLE BOND; R2, R3 AND R5 ARE H, ALKYL, ARYL, AMONG OTHERS; R4 IS H, ALKYL, ALKENYL, AMONG OTHERS; R6 IS H, RENT OR SUBSTITUTE RENT; R12 IS H, RENT, SUBSTITUTE RENT, OR HALOGEN; R13 IS ARYLUS, HETEROARYL, AMONG OTHERS; m IS AN INTEGER FROM 0 TO 6. IT IS ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE USEFUL IN THE TREATMENT OF CANCERS, ESPECIALLY THOSE RELATED TO THE EXPRESSION OF THE FOLATE RECEIVER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80836606P | 2006-05-25 | 2006-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080316A1 true PE20080316A1 (en) | 2008-04-10 |
Family
ID=38561739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000648A PE20080316A1 (en) | 2006-05-25 | 2007-05-24 | AZIRIDINYL-EPOTILONE COMPOUNDS |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7872145B2 (en) |
| EP (1) | EP2041140B1 (en) |
| JP (1) | JP5249929B2 (en) |
| KR (1) | KR101413955B1 (en) |
| CN (1) | CN101495482B (en) |
| AR (1) | AR061181A1 (en) |
| AT (1) | ATE524477T1 (en) |
| AU (1) | AU2007267535B2 (en) |
| BR (1) | BRPI0712167A2 (en) |
| CA (1) | CA2655668C (en) |
| EA (1) | EA014872B1 (en) |
| ES (1) | ES2371111T3 (en) |
| IL (1) | IL195236A (en) |
| MX (1) | MX2008014735A (en) |
| NO (1) | NO20084742L (en) |
| NZ (1) | NZ572763A (en) |
| PE (1) | PE20080316A1 (en) |
| TW (1) | TWI383985B (en) |
| WO (1) | WO2007140297A2 (en) |
| ZA (1) | ZA200810022B (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010528115A (en) | 2007-05-25 | 2010-08-19 | ブリストル−マイヤーズ スクイブ カンパニー | Epothilone compound and method for producing analog |
| CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| MX371403B (en) | 2014-03-20 | 2020-01-29 | Bristol Myers Squibb Co | Stabilized fibronectin based scaffold molecules. |
| CA2968382A1 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| SMT202000413T1 (en) | 2014-11-21 | 2020-09-10 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| SG11201703760WA (en) | 2014-11-25 | 2017-06-29 | Bristol Myers Squibb Co | Novel pd-l1 binding polypeptides for imaging |
| JP2018510864A (en) | 2015-03-10 | 2018-04-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Antibody capable of binding by transglutaminase and conjugate produced thereby |
| CN108137687B (en) | 2015-05-29 | 2021-10-29 | 百时美施贵宝公司 | Anti-OX40 antibody and its use |
| US10584160B2 (en) | 2015-09-23 | 2020-03-10 | Bristol-Myers Squibb Company | Glypican-3-binding fibronectin based scaffold molecules |
| AU2016340093A1 (en) * | 2015-10-16 | 2018-05-10 | William Marsh Rice University | Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof |
| KR20180089433A (en) | 2015-12-21 | 2018-08-08 | 브리스톨-마이어스 스큅 컴퍼니 | Variant antibodies for site-specific conjugation |
| SG10201913033UA (en) | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| KR102085798B1 (en) | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | Compounds comprising beta-galactoside self-immolative linker |
| CN116333129A (en) | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | Antibodies comprising modified heavy chain constant regions |
| US20220106400A1 (en) | 2018-11-28 | 2022-04-07 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| CN113453725A (en) | 2018-11-30 | 2021-09-28 | 百时美施贵宝公司 | Antibodies comprising glutamine-containing light chain C-terminal extensions, conjugates thereof, and methods and uses |
| CN113544155A (en) | 2018-12-12 | 2021-10-22 | 百时美施贵宝公司 | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
| CN110563730B (en) * | 2019-07-29 | 2022-03-25 | 江苏理工学院 | High purity N10Preparation method of (E) -trifluoroacetyl pteroic acid |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| EP4178982A1 (en) | 2020-07-13 | 2023-05-17 | Precirix N.V. | Antibody fragment against folr1 |
| EP4079327A1 (en) * | 2021-04-22 | 2022-10-26 | Centaurus Polytherapeutics | Payloads for drug-conjugates and their use for treating cancer |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| EP4518911A1 (en) | 2022-05-02 | 2025-03-12 | Precirix N.V. | Pre-targeting |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US6291673B1 (en) | 1997-10-17 | 2001-09-18 | Purdue Research Foundation | Folic acid derivatives |
| US6380395B1 (en) * | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
| US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
| AUPQ014799A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
| US6800653B2 (en) | 2001-06-01 | 2004-10-05 | Bristol-Myers Squibb Compnay | Epothilone derivatives |
| EP1524979A2 (en) | 2002-07-31 | 2005-04-27 | Schering AG | New effector conjugates, process for their production and their pharmaceutical use |
| EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| TWI405573B (en) * | 2003-01-27 | 2013-08-21 | Endocyte Inc | Vitamin-receptor binding drug delivery conjugates intermediates and preparation processes |
| DE602005003453T2 (en) | 2004-01-30 | 2008-09-25 | Bayer Schering Pharma Aktiengesellschaft | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR MANUFACTURE AND THEIR PHARMACEUTICAL USE |
| CN101438252A (en) | 2004-10-07 | 2009-05-20 | 爱莫里大学 | Multifunctional nanoparticle conjugates and their use |
-
2007
- 2007-05-24 PE PE2007000648A patent/PE20080316A1/en not_active Application Discontinuation
- 2007-05-24 AR ARP070102263A patent/AR061181A1/en not_active Application Discontinuation
- 2007-05-25 BR BRPI0712167-9A patent/BRPI0712167A2/en not_active IP Right Cessation
- 2007-05-25 ES ES07762325T patent/ES2371111T3/en active Active
- 2007-05-25 EP EP07762325A patent/EP2041140B1/en active Active
- 2007-05-25 EA EA200802389A patent/EA014872B1/en not_active IP Right Cessation
- 2007-05-25 US US11/753,785 patent/US7872145B2/en not_active Ceased
- 2007-05-25 AU AU2007267535A patent/AU2007267535B2/en not_active Ceased
- 2007-05-25 CA CA2655668A patent/CA2655668C/en not_active Expired - Fee Related
- 2007-05-25 KR KR1020087031405A patent/KR101413955B1/en not_active Expired - Fee Related
- 2007-05-25 JP JP2009512317A patent/JP5249929B2/en not_active Expired - Fee Related
- 2007-05-25 TW TW096118882A patent/TWI383985B/en not_active IP Right Cessation
- 2007-05-25 MX MX2008014735A patent/MX2008014735A/en active IP Right Grant
- 2007-05-25 WO PCT/US2007/069736 patent/WO2007140297A2/en not_active Ceased
- 2007-05-25 CN CN200780028309XA patent/CN101495482B/en not_active Expired - Fee Related
- 2007-05-25 AT AT07762325T patent/ATE524477T1/en not_active IP Right Cessation
- 2007-05-25 NZ NZ572763A patent/NZ572763A/en not_active IP Right Cessation
-
2008
- 2008-11-10 NO NO20084742A patent/NO20084742L/en not_active Application Discontinuation
- 2008-11-11 IL IL195236A patent/IL195236A/en not_active IP Right Cessation
- 2008-11-25 ZA ZA2008/10022A patent/ZA200810022B/en unknown
-
2011
- 2011-04-18 US US13/089,067 patent/USRE42930E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101495482B (en) | 2012-05-02 |
| TW200815452A (en) | 2008-04-01 |
| WO2007140297A3 (en) | 2008-01-31 |
| CN101495482A (en) | 2009-07-29 |
| IL195236A0 (en) | 2009-08-03 |
| EP2041140B1 (en) | 2011-09-14 |
| US7872145B2 (en) | 2011-01-18 |
| JP2009538349A (en) | 2009-11-05 |
| EA200802389A1 (en) | 2009-06-30 |
| AU2007267535B2 (en) | 2012-07-05 |
| AU2007267535A8 (en) | 2011-06-09 |
| KR101413955B1 (en) | 2014-07-01 |
| CA2655668A1 (en) | 2007-12-06 |
| HK1124335A1 (en) | 2009-07-10 |
| NZ572763A (en) | 2010-08-27 |
| US20070276018A1 (en) | 2007-11-29 |
| ZA200810022B (en) | 2011-05-25 |
| AU2007267535A1 (en) | 2007-12-06 |
| BRPI0712167A2 (en) | 2012-08-28 |
| IL195236A (en) | 2012-12-31 |
| USRE42930E1 (en) | 2011-11-15 |
| CA2655668C (en) | 2013-02-26 |
| ES2371111T3 (en) | 2011-12-27 |
| AR061181A1 (en) | 2008-08-13 |
| JP5249929B2 (en) | 2013-07-31 |
| NO20084742L (en) | 2008-12-16 |
| EP2041140A2 (en) | 2009-04-01 |
| EA014872B1 (en) | 2011-02-28 |
| TWI383985B (en) | 2013-02-01 |
| ATE524477T1 (en) | 2011-09-15 |
| MX2008014735A (en) | 2009-02-12 |
| WO2007140297A2 (en) | 2007-12-06 |
| KR20090025266A (en) | 2009-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080316A1 (en) | AZIRIDINYL-EPOTILONE COMPOUNDS | |
| PE20140961A1 (en) | MACROCYCLIC INHIBITORS OF SERINE PROTEASES OF HEPATITIS C | |
| PE20080102A1 (en) | AZIRIDINYL-EPOTILONE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME | |
| MXPA05011166A (en) | Cgrp receptor antagonists. | |
| CO6160237A2 (en) | PIRAZINONAS AND PIRAZINOLES REPLACED AND COMPOSITIONS THAT INCLUDE THEM | |
| CR20140316A (en) | DERIVATIVES OF INDOL AS RECEIVING ANTAGONISTS OF S1P1 (DIVISIONAL 10922) | |
| ATE429427T1 (en) | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | |
| EA200702497A1 (en) | SUBSTITUTED Arylpyrazoles for use against parasites | |
| RU2010102229A (en) | Benzazepine derivatives suitable for use as antagonists of vasopressin | |
| IL182317A0 (en) | Cgrp receptor antagonists | |
| MXPA05010824A (en) | Bicyclic compounds as nr2b receptor antagonists. | |
| GT200500101A (en) | METHYL-ARIL OR HETEROARIL-AMIDA SUBSTITUTED COMPOUNDS | |
| SG162805A1 (en) | Pyrazine derivatives useful as adenosine receptor antagonists | |
| ATE466860T1 (en) | CGRP RECEPTOR ANTAGONISTS | |
| PE20090042A1 (en) | CYCLOPAMINE ANALOGS | |
| MA28550B1 (en) | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | |
| TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| MY147400A (en) | Heterocyclic compounds as ccr2b antagonists | |
| PE20060625A1 (en) | BENZAZEPINE DERIVATIVES AS ANTAGONISTS AND / OR AGONISTS OF THE HISTAMINE H3 RECEPTOR | |
| TW200510427A (en) | Novel fused heterocycles and uses thereof | |
| EP1804919A4 (en) | CGRP RECEPTOR ANTAGONISTS | |
| IL178839A0 (en) | Heterocyclic condensed compounds useful as antidiuretic agents | |
| EA200500899A1 (en) | ANTAGONISTS OF ADDROSE DIPHOSPHATE PLATELET RECEPTOR | |
| GB0507601D0 (en) | Compounds | |
| PE20050336A1 (en) | TRICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN FARNESIL TRANSFERASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |